ALT
Altimmune
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Altimmune initiated the Phase 3 PERFORMA trial of pemvidutide in patients with MASHAug 3, 2026
- Altimmune reports positive topline Phase 2 RECLAIM results for pemvidutide in alcohol use disorderJul 28, 2026
- Altimmune receives FDA Breakthrough Therapy designation for pemvidutide in MASHJan 5, 2026
- Altimmune announces early completion of enrollment in RECLAIM Phase 2 trial evaluating pemvidutide in alcohol use disorderNov 3, 2025
- Altimmune announces FDA Fast Track designation for Pemvidutide in alcohol use disorderAug 19, 2025